OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Dreicer on Response to Immunotherapy in Urothelial Cancer

September 6th 2019

Robert Dreicer, MD, deputy director, UVA Cancer Center, director, Solid Tumor Oncology in the Division of Hematology/Oncology, and a professor of Medicine and Urology, University of Virginia Health System, discusses response to immunotherapy in urothelial cancer.

Dr. Ramalingam on the Activity of Osimertinib Combinations in NSCLC

September 6th 2019

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Larson on Potentially Practice-Changing Data in Frontline Multiple Myeloma

September 6th 2019

Sarah M. Larson, MD, discusses potentially practice-changing studies for patients with transplant-eligible and -ineligible multiple myeloma.

Dr. Jain on Radioligand Therapy in Prostate Cancer

September 5th 2019

Manoj K. Jain, MD, discusses the use of radioligand therapy in prostate cancer.

Dr. Fujioka on Remaining Questions After the PACIFIC Trial in NSCLC

September 5th 2019

Naomi Fujioka, MD, discusses the questions that remain after the PACIFIC trial in stage III non–small cell lung cancer.

Dr. Farago on Effectiveness of Single-Agent Lurbinectedin in SCLC

September 4th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the phase II trial results using the marine-based drug lurbinectedin as a single agent treatment inpatients with small cell lung cancer.

Dr. Singh on Research With Antibody-Drug Conjugates in Advanced Bladder Cancer

September 4th 2019

Parminder Singh, MD, hematologist/oncologist, Mayo Clinic, discusses research being done with antibody-drug conjugates (ADCs) in advanced bladder cancer.

Dr. McCulloch on the Likelihood of Relapse on a BTK Inhibitor in MCL

September 4th 2019

Rory McCulloch, MD, vice chair, South West Peninsula, HaemSTAR, hematology registrar, University Hospitals, Plymouth, discusses the likelihood of relapse on a BTK inhibitor in mantle cell lymphoma (MCL).

Dr. Marks on the Role of TKIs in HER2-Positive Breast Cancer

September 4th 2019

Douglas K. Marks, MD, clinical instructor, Department of Medicine, Perlmutter Cancer Center, NYU Langone Health, discusses the role of TKIs in HER2-positive breast cancer.

Experts Share Key Aspects of Cancer Care That Warrant Additional Publicity

September 4th 2019

OncLive interviewed experts at the State of the Science Summits in August 2019 on aspects of care in their field that they wish were publicized more.

Dr. Mirza on Efficacy of Niraparib/Bevacizumab Combo in Recurrent Ovarian Cancer

September 4th 2019

Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses results from the phase II NSGO-AVANOVA2/ENGOT-OV24 trial comparing niraparib with niraparib plus bevacizumab in patients with recurrent platinum-sensitive ovarian cancer.

Dr. Manji on Treatment for Right-Sided Tumors in CRC

September 4th 2019

Gulam A. Manji, MD, PhD, discusses the difference between right- and left-sided tumors in colorectal cancer and the appropriate treatment for right-sided tumors based on a subgroup analysis.

Dr. Kolberg on Collecting Real-World Biosimilar Trastuzumab Data in Breast Cancer

September 4th 2019

Hans-Christian Kolberg, MD, discusses collecting real-world data for biosimilars, specifically the trastuzumab biosimilar ABP 980 for breast cancer.

Dr. Joseph on Molecular Signatures in mRCC

September 4th 2019

Richard W. Joseph, MD, internist and oncologist, Mayo Clinic, discusses molecular signatures in metastatic renal cell carcinoma (mRCC).

Dr. Kohli on Sequencing Concerns in Metastatic Hormone-Sensitive Prostate Cancer

September 4th 2019

Manish Kohli, MD, vice chair, Department of Genitourinary Oncology, Moffitt Cancer Center, discusses sequencing concerns in metastatic hormone-sensitive prostate cancer (mHSPC).

Dr. Davis on Immunotherapy in HER2-Positive Gastric/GEJ Cancer

September 4th 2019

S. Lindsey Davis, MD, an assistant professor of medicine and gastrointestinal medical oncologist at the University of Colorado Cancer Center, discusses an investigational immunotherapy combination being explored in patients with HER2-positive gastric and gastroesophageal junction (GEJ) cancer.

Dr. Pinato on Molecular Characterization of Tumor Microenvironment in NETs

September 3rd 2019

David J. Pinato, MD, PhD, clinical senior lecturer in medical oncology, clinician scientist, consultant medical oncologist, Department of Surgery and Cancer, Imperial College London, discusses the molecular makeup of the tumor microenvironment in neuroendocrine malignancies.

Dr. D'Angelo on Bempegaldesleukin/Nivolumab Combo in Sarcomas

September 3rd 2019

Sandra P. D’Angelo, MD, medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the results of a pilot study investigating the combination of bempegaldesleukin (NKTR-214) plus nivolumab (Opdivo) in patients with sarcomas.

Dr. Wakelee on First Trial to Combine Antiangiogenic Agents With Immunotherapy in NSCLC

August 30th 2019

Heather A. Wakelee, MD, medical oncologist, thoracic specialist, professor of medicine at Stanford University, discusses results from the phase III IMpower150 trial in non–small cell lung cancer.

Dr. Welslau on Financial Savings of Biosimilar Rituximab in DLBCL

August 30th 2019

Manfred Welslau, MD, discusses financial savings of using a rituximab biosimilar for patients with previously untreated CD20-positive diffuse large B-cell lymphoma.